Comprehensive Guide to Immunotherapy and Clinical Trials
PD-L1 (Programmed Death Ligand-1) is a protein found on many lung cancer cells that helps them evade the immune system. Measuring PD-L1 expression is crucial for determining immunotherapy eligibility. High PD-L1 expression often indicates better response to checkpoint inhibitor immunotherapies, though low or negative tumors may also benefit in combination settings.
PD-L1 expression is measured using immunohistochemistry (IHC) on tumor tissue. The level is reported as a percentage of tumor cells expressing the protein. Expression is typically categorized as: negative (0%), low (1-49%), or high (≥50%). The test helps oncologists decide whether checkpoint inhibitor immunotherapy is appropriate for each patient.
No or minimal PD-L1 expression. Single-agent checkpoint inhibitors have lower response rates, but combination approaches and other immunotherapy strategies may still benefit some patients.
Intermediate PD-L1 expression. Response to checkpoint inhibitors is variable. Combination therapy with chemotherapy often recommended over single-agent immunotherapy.
High PD-L1 expression. Best candidates for single-agent checkpoint inhibitor therapy with highest response rates and superior outcomes in many cases.
High PD-L1 expression (≥50%) suggests your cancer is likely to respond well to checkpoint inhibitor immunotherapy. Patients with high PD-L1 typically benefit from single-agent checkpoint inhibitors as first-line treatment, with response rates ranging from 40-50% and often better outcomes compared to chemotherapy. Your oncologist will recommend the most appropriate agent based on your specific situation.
Low or negative PD-L1 tumors are less likely to respond to single-agent checkpoint inhibitors. In these cases, oncologists typically recommend combination therapy pairing chemotherapy with a checkpoint inhibitor, which shows better outcomes than chemotherapy alone. Some patients may still benefit from immunotherapy in combination settings or other approaches.
PD-L1 is tested using immunohistochemistry (IHC) on a tissue sample, usually obtained during initial diagnosis. PD-L1 expression can change over time and during treatment, particularly with chemotherapy or other exposures. For some patients, repeat testing may be recommended if initial tests are borderline or if there's significant time between diagnosis and treatment start.
FDA-approved checkpoint inhibitors for lung cancer include pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq). These drugs work by blocking the PD-1/PD-L1 pathway, allowing the immune system to attack cancer cells more effectively. Other checkpoint inhibitor combinations are also approved for specific settings. Your oncologist will choose the best option based on your PD-L1 status and other factors.
Yes, there are numerous active clinical trials testing new checkpoint inhibitors, combination strategies, and approaches to improve outcomes for PD-L1+ and PD-L1- patients. Trials may explore combining checkpoint inhibitors with targeted therapies, chemotherapy, or other novel agents. Use our search tool to find trials matching your PD-L1 status and other characteristics.
Search our comprehensive database of clinical trials for PD-L1 expression and immunotherapy research.